Your session is about to expire
← Back to Search
DPX-Survivac + Immunotherapy for Advanced Cancers
Study Summary
This trial will test a new cancer treatment involving two drugs and immunotherapy. The goal is to see if it is safe and effective for treating certain types of advanced and recurrent solid tumors.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received a transplanted organ or tissue from another person.You recently received vaccines that contain weakened viruses.You are expected to live for at least 6 more months.You have current or ongoing skin or blood vessel problems.You have significant swelling in your legs or feet.You have received a vaccine or other treatments that target survivin or boost the immune system in the past.You have another type of cancer, except for non-melanoma skin cancer, early-stage cervical cancer, or controlled bladder cancer.You have a buildup of fluid in your abdomen or chest that cannot be treated or controlled.You have a blockage in your intestines that is caused by cancer or a recent history of such a blockage.You have an autoimmune disease that needed treatment within the past two years (except for replacement therapy).You have recently had thyroid inflammation.You have a history of lung inflammation or currently have lung inflammation that needs treatment with steroids.You have cancer that has spread to your brain or the membranes surrounding your brain.You have a stomach or intestinal condition that may make it difficult for your body to absorb medicine taken by mouth.You have recently had a heart attack or stroke, or you have other serious ongoing health problems.You have a severe allergic reaction (Grade 3 or higher) to pembrolizumab.You have received chemotherapy or immunotherapy within the past 28 days before the study.You have previously been treated with a medication that affects the immune system and had severe side effects (Grade 3 or higher).You have advanced or spreading solid tumors and have already finished your initial treatment.
- Group 1: Arm 1 (All cohorts)
- Group 2: Arm 2 (Ovarian cohort only)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How widespread is the reach of this clinical investigation?
"This trial has 18 sites recruiting patients, including the Boca Raton Regional Hospital, Lynn Cancer Institute in Boca Raton, CHUM hospital in Montreal and Comprehensive Hematology and Oncology from Saint Petersburg. Additionally, there are 14 other locations across North America."
What is the intake capacity for patients in this experiment?
"Sadly, this clinical trial is no longer accepting new patients. It was initially posted on December 21st 2018 and last updated March 28th 2022. However, 1464 studies that involve carcinoma hepatocellular are still recruiting participants as well as 1746 DPX-Survivac trials currently seeking individuals for their research."
Are there opportunities for volunteers to join the current research experiment?
"Unfortunately, this medical study is not currently enrolling participants. The trial first appeared on December 21st 2018 and was last updated on March 28th 2022. If you are searching for other trials, 1464 clinical studies using carcinoma hepatocellular treatments are actively recruiting patients while 1746 DPX-Survivac trials have open spots available."
What maladies does DPX-Survivac typically target?
"DPX-Survivac is generally employed for malignant melanoma of skin treatment, yet it also has been shown to be efficacious in the management of recurrent cervical cancer, leukemia, refractory and relapsed mediastinal large B-cell lymphoma."
Has DPX-Survivac been officially endorsed by the FDA?
"Our team's assessment of DPX-Survivac safety is a 2, as it has completed Phase 2 clinical trials and there are some data points suggesting its security but none supporting effectiveness."
What other experiments have been conducted regarding the effectiveness of DPX-Survivac?
"In 1997, the City of Hope Comprehensive Cancer Center launched its first trial on DPX-Survivac. Since then, 1329 studies have been wrapped up with 1746 trials active at present - many of which are conducted in Boca Raton, FL."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger